# DESCRIPTION

## FIELD OF THE INVENTION

- relate to clinical diagnostics

## BACKGROUND OF THE INVENTION

- motivate insulin resistance
- discuss nicotinamide-N-methyltransferase

### Technical Problems Underlying the Present Invention

- limitations of prior art

## SUMMARY OF THE INVENTION

- method of determining treatment benefit
- method of determining treatment response

## DETAILED DESCRIPTION

### Definitions

- define terminology
- explain usage of "comprise"
- clarify incorporation by reference
- define "about"
- define body mass index (BMI)
- define inhibitor of nicotinamide-N-methyltransferase (NNMT)
- define level of 1-methylnicotinamide (MNA)
- define small molecule
- define peptide
- define nucleic acid
- define reference value and pre-treatment value

### EMBODIMENTS OF THE INVENTION

- introduce method of determining whether patient will benefit from NNMT inhibitor treatment
- describe comparison of MNA levels
- introduce method of determining whether patient responds to NNMT inhibitor treatment
- describe comparison of MNA levels
- introduce method of adjusting dose of therapeutic drug
- describe comparison of MNA levels
- introduce method for determining degree of insulin resistance
- describe comparison of MNA levels
- specify types of inhibitors of NNMT
- specify types of patients

### EXAMPLES

- provide examples of the invention
- describe study population and methods
- define inclusion and exclusion criteria
- outline exercise intervention protocol
- describe measurement of body fat content and glucose metabolism
- detail analysis of blood samples
- describe NNMT mRNA expression studies
- outline LCMSMS measurements for MNA concentrations
- describe statistical analysis methods
- present results of study, including anthropometric and clinical characteristics
- show association of NNMT expression with T2D
- describe correlation between plasma MNA concentrations and adipose tissue NNMT expression
- present results of exercise intervention on adipose tissue NNMT expression
- show correlation between plasma MNA concentrations and insulin resistance
- describe change in plasma MNA concentrations upon administration of NNMT inhibitor
- present results of NNMT inhibitor administration in mice
- summarize results and implications

